Higher levels of von Willebrand Factor in hospitalised patient plasma provides an explanation for the association of ABO blood group and secretor status with COVID19 severity

Tosti J Mankelow*, Allison Blair, David T Arnold, Fergus W Hamilton, Kathleen M Gillespie, David J Anstee, Ash M Toye*

*Corresponding author for this work

Research output: Contribution to journalComment/debate (Academic Journal)peer-review

2 Citations (Scopus)
39 Downloads (Pure)

Abstract

[No abstract]
Original languageEnglish
Pages (from-to)261-262
Number of pages2
JournalTransfusion Medicine
Volume32
Issue number3
Early online date24 Mar 2022
DOIs
Publication statusE-pub ahead of print - 24 Mar 2022

Bibliographical note

Funding Information:
This work was supported by the National Institute for Health Research Blood and Transplant Research Unit (NIHR BTRU) in Red Cell Products (IS‐BTU‐1214‐10032) and the Department of Health (England) (National Health Service Blood and Transplant research and development grant ‐ WP15‐04). The views expressed are those of the authors and not necessarily those of the National Health Service, NIHR, or the Department of Health and Social Care. The authors apologise that not all references relevant to this letter could be cited because of reference number limits imposed by the journal. The authors dedicate this manuscript to the memory of Professor David Anstee who, early in the pandemic (February 2020), had the foresight to initiate our investigation into secretor status alongside ABO group in association with COVID19 disease severity and who then went on to make the link with VWF that led to this study. Although Prof Anstee approved the content presented in the manuscript, he sadly died before submission. 5

Funding Information:
This work was supported by the National Institute for Health Research Blood and Transplant Research Unit (NIHR BTRU) in Red Cell Products (IS-BTU-1214-10032) and the Department of Health (England) (National Health Service Blood and Transplant research and development grant - WP15-04). The views expressed are those of the authors and not necessarily those of the National Health Service, NIHR, or the Department of Health and Social Care. The authors apologise that not all references relevant to this letter could be cited because of reference number limits imposed by the journal. The authors dedicate this manuscript to the memory of Professor David Anstee who, early in the pandemic (February 2020), had the foresight to initiate our investigation into secretor status alongside ABO group in association with COVID19 disease severity5 and who then went on to make the link with VWF that led to this study. Although Prof Anstee approved the content presented in the manuscript, he sadly died before submission.

Fingerprint

Dive into the research topics of 'Higher levels of von Willebrand Factor in hospitalised patient plasma provides an explanation for the association of ABO blood group and secretor status with COVID19 severity'. Together they form a unique fingerprint.

Cite this